pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,756 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT834Endpoints640BioPharma Dive243onclive165BioSpace98Fierce Biotech96raps39globenewswire health28fda recalls
therapy area
allOncology5003Rare Disease850Cardiology802Hematology770Immunology733Psychiatry & CNS582Pulmonology
  • STAT+: New obesity tool aims to predict risk of 18 serious complications
    A new tool, OBSCORE, is meant to better define who's at risk for obesity complications, going beyond BMI to include family history, diet, and more.
    STAT · 3mo ago↗ source
  • Opinion: Are international medical graduates taking residency spots from Americans? We did the math
    A new social media narrative claims international grads are stealing American doctors’ jobs. These authors did the math to figure out if it’s true.
    STAT · 3mo ago↗ source
  • Securing NIH awards is getting more competitive — and confusing
    The likelihood of snagging NIH grants has plunged to historic lows, forcing academic researchers to resort to a variety of tactics to try to obtain funding
    STAT · 3mo ago↗ source
← prev
page 65 of 71
next →
23
fda press21
fda medwatch18
570
Vaccines517
Endocrinology & Metabolism291
Ophthalmology258
Infectious Disease253
Nephrology239
  • Opinion: Congress must hold RFK Jr. accountable after hearings
    Michael Burgess and Larry Bucshon, former Republican congressmen and doctors, weigh in on RFK Jr.’s recent congressional hearings.
    STAT · 3mo ago↗ source
  • Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
    The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.
    BioPharma Dive · 3mo ago↗ source
  • HHS appeals ruling that stalled many of Kennedy’s vaccine policy changes
    The appeal is the latest twist in the closely watched lawsuit filed by the American Association of Pediatrics.
    STAT · 3mo ago↗ source
  • STAT+: Supreme Court justices appear to signal ‘skinny labeling’ can survive
    At Wednesday's argument, the justices did not appear to question whether skinny labeling is valid.
    STAT · 3mo ago↗ source
  • AbbVie faces questions about Skyrizi competition from J&J
    Threats to AbbVie's immunology dominance took center stage on the company's first-quarter earnings call Wednesday morning, as analysts pressed executives on their defense strategy. The heart of the…
    Endpoints · 3mo ago↗ source
  • FDA, AstraZeneca prep for oncology adcomm
    The FDA is set to convene its first advisory meeting of oncology experts in about nine months, with a couple of AstraZeneca drugs as the focus of the discussion. Details about the meeting of the ...
    Endpoints · 3mo ago↗ source
  • STAT+: Why conversations around health AI may be evolving beyond hype
    In this edition of AI Prognosis, Brittany Trang argues that the tide may be turning when it comes to how the health care industry talks about AI.
    STAT · 3mo ago↗ source
  • Teva nabs experimental Tourette drug in $700M Emalex buyout
    A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.
    BioPharma Dive · 3mo ago↗ source
  • Chiesi to buy KalVista in $1.9B deal for rare disease drug
    The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.
    BioPharma Dive · 3mo ago↗ source
  • Bristol Myers reaches a crossroads as a make-or-break year takes shape
    Bristol Myers Squibb is facing a bit of an identity crisis. CEO Chris Boerner is nearly two and a half years into his tenure, with most of his time defined by
    Endpoints · 3mo ago↗ source
  • Pfizer earns positive Phase 3 in multiple myeloma; ICON overstated revenue
    Pfizer’s positive Phase 3 data in multiple myeloma: The company’s Elrexfio produced a “statistically significant and clinically meaningful improvement” in progression-free survival in patients with…
    Endpoints · 3mo ago↗ source
  • FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
    Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multipl…
    BioPharma Dive · 3mo ago↗ source
  • Infant formula largely safe from heavy metals, FDA finds
    FDA sampled 312 major infant formula brands and found low or undetectable levels of pesticide residue, PFAS, heavy metals and phthalates.
    STAT · 3mo ago↗ source
  • After Apellis deal, Biogen looks to fill early-stage pipeline
    Biogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we're going to be focusing on is early-stage development and res…
    Endpoints · 3mo ago↗ source
  • AstraZeneca rekindles UK relationship, pledges £300M to expand
    AstraZeneca and the UK government are back in each other's good graces. AstraZeneca on Wednesday said it is lifting its UK investment pause, with a £300 million budget to finish construction of a n…
    Endpoints · 3mo ago↗ source
  • STAT+: A patent win for Pfizer and BridgeBio
    A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout
    STAT · 3mo ago↗ source
  • Chiesi signs $1.9B deal to acquire KalVista and its approved drug
    Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KAL…
    Endpoints · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more
    The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials conducted by AstraZeneca and Amgen
    STAT · 3mo ago↗ source
  • Should pharma be swinging bigger with AI? One top researcher wants to try
    RIO DE JANEIRO — Kyunghyun Cho says he's a free man once again. He makes that observation, semi-jokingly, while looking over countless rows of poster presentations on the sidelines of the Internati…
    Endpoints · 3mo ago↗ source
  • Food safety experts warn of USDA brain drain
    An autism advisory committee finally meets again, antipsychotics and dementia, and more health news from Morning Rounds
    STAT · 3mo ago↗ source
  • GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts
    GSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels said during its first-quarter earnings call with…
    Endpoints · 3mo ago↗ source
  • MPM has collected three China drugs for its ‘best of both worlds’ strategy
    MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year, its portfolio company K2 Therapeutics has amassed three…
    Endpoints · 3mo ago↗ source